OncoSil Medical LtdASX: OSL

OncoSil Medical: Half Yearly Report Results

· Issued by OncoSil Medical Ltd

Filed with ASX · · 3 pages · English

Sydney, Australia – 22 February 2022: OncoSil Medical Ltd (ASX: OSL) (OncoSil or the Company), a medical device company focused on localised treatments for patients with pancreatic cancer, is pleased to report its financial results for the half year ended 31 December 2021 (the Half-Year) (the Financial Report) and its Appendix 4D. All financial results are in Australian dollars and are unaudited.

OncoSil Medical Ltd on 6ix

Earlier from OncoSil Medical

Later from OncoSil Medical

All OncoSil Medical news releases